Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
Josefina Marin, María Laura Acosta Felquer, Enrique R Soriano Rheumatology Unit, Internal Medical Serivces, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina Abstract: Certolizumab pegol (CZP) is a pegylated huma...
Guardado en:
Autores principales: | Marin J, Acosta Felquer ML, Soriano ER |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d7db2130f257427ab00260fb3fb0170b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
por: Acosta-Felquer ML, et al.
Publicado: (2016) -
The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
por: Eric Toussirot, et al.
Publicado: (2021) -
Takayasu’s arteritis occurring under TNF blockers in a patient with spondyloarthritis: is it an association or a paradoxical effect?
por: Amel Rezgui, et al.
Publicado: (2021) -
Prediction of Treatment Response According to ASAS-EULAR Management Recommendations in 1 Year for Hip Involvement in Axial Spondyloarthritis Based on MRI and Clinical Indicators
por: Zhuoyao Xie, et al.
Publicado: (2021) -
Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
por: Santos-Moreno P, et al.
Publicado: (2021)